Thiolactomycin is an inhibitor of type I1 dissociable fatty acid synthases from plants and bacteria [ 1 1. The three P-ketoacyl acyl carrier protein (ACP) synthases in peas are all inhibited by thiolactomycin [2] . Condensing enzyme I1 (KAS II), which catalyses the elongation of palmitoyl-ACP to stearoyl-ACP is the most sensitive and the short chain condensing enzyme (KAS III), which catalyses the initial condensation of acetyl-CoA with malonyl-ACP, the least sensitive [2] . There is some evidence that acetyl-CoA: ACP transacylase activity is also inhibited but the other enzymes of fatty acid synthesis appear to be unaffected [2, 31. Table 1 shows that several of the analogues produce greater inhibition of fatty acid synthesis than thiolactomycin itself Thiolactomycin has a polar head group and a 5 carbon hydrophobic side chain (see legend to Table 1 ). Apart from analogue 7, which contains a nitrile group and gave rather inconsistent results, the most effective analogue structures are 5 and 6, both of which are more hydrophobic than thiolactomycin. Analogue 4 which is a straight-chain hydrocarbon but less hydrophobic than thiolactomycin give a inhibition, though not so much as thiolactomycin itself The shorter side chain of analogue 2 and the epoxy side-group of analogue 3 produced no inhibition at all. Hydrophobicity and length of the side chain therefore appear to 
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7 . KAS II is less susceptible [7] and KAS 111 unaffected by cerulenin [3] . Cerulenin is also an irreversible inhibitor of multihnctional fatty acid synthases which are insensitive to thiolactomycin [6] .
The action of thiolactomycin appears to be reversible [7] and it has been wggested to be a competitive inhibitor with respect to malonyl-ACP.
acids labelled from [ I-Wlacetate by chloroplasts, giving an increase in the proportion of labelling of short-chain fatty acids [Jones and Hanvood, unpublished data] . There is some indication that the inhibitory analogues also have this effect, implying that they too inhibit KAS II more than KAS I and both to a greater degree than KAS 111. The analogues that produced no inhibition did not change the labelling of fatty acids. In some cases analogues that inhibited at one concentration actually appeared to produce increases in lipid labelling at lower concentrations -this occurred with analogues 6 and 7.
We are also using molecular modelling software to model thiolactomycin, cerulenin and the analogues to see if this yields any interesting comparisons which will explain the mechanism of condensing enzyme inhibition.
Thiolactomycin produces a distinct change in the pattern of fatty This is a LINK project supported by AFRC, SERC and AgrEvo UK Limited.
